Literature DB >> 34006281

The role of mpMRI in qualification of patients with ISUP 1 prostate cancer on biopsy to radical prostatectomy.

Łukasz Nyk1, Omar Tayara1, Tomasz Ząbkowski2, Piotr Kryst1, Aneta Andrychowicz3, Wojciech Malewski1.   

Abstract

BACKGROUND: To investigate the role of mpMRI and high PIRADS score as independent triggers in the qualification of patients with ISUP 1 prostate cancer on biopsy to radical prostatectomy.
METHODS: Between January 2017 and June 2019, 494 laparoscopic radical prostatectomies were performed in our institution, including 203 patients (41.1%) with ISUP 1 cT1c-2c PCa on biopsy. Data regarding biopsy results, digital rectal examination, PSA, mpMRI and postoperative pathological report have been retrospectively analysed.
RESULTS: In 183 cases (90.1%) mpMRI has been performed at least 6 weeks after biopsy. Final pathology revealed ISUP Gleason Grade Group upgrade in 62.6% of cases. PIRADS 5, PIRADS 4 and PIRADS 3 were associated with Gleason Grade Group upgrade in 70.5%, 62.8%, 48.3% of patients on final pathology, respectively. Within PIRADS 5 group, the number of upgraded cases was statistically significant.
CONCLUSIONS: PIRADS score correlates with an upgrade on final pathology and may justify shared decision of radical treatment in patients unwilling to repeated biopsies. However, the use of PIRADS 5 score as a sole indicator for prostatectomy may result in nonnegligible overtreatment rate.

Entities:  

Keywords:  Active surveillance; Gleason upgrading; MpMRI of prostate; PIRADS score; Prostate cancer

Year:  2021        PMID: 34006281     DOI: 10.1186/s12894-021-00850-3

Source DB:  PubMed          Journal:  BMC Urol        ISSN: 1471-2490            Impact factor:   2.264


  3 in total

1.  The pathological upgrading after radical prostatectomy in low-risk prostate cancer patients who are eligible for active surveillance: How safe is it to depend on bioptic pathology?

Authors:  Samed Verep; Selcuk Erdem; Yasemin Ozluk; Isin Kilicaslan; Oner Sanli; Faruk Ozcan
Journal:  Prostate       Date:  2019-07-03       Impact factor: 4.104

2.  Multicenter analysis of pathological outcomes of patients eligible for active surveillance according to PRIAS criteria.

Authors:  Angelica A Grasso; Gabriele Cozzi; Elisa DE Lorenzis; Carlo Ceruti; Simone Crivellaro; Mario Falsaperla; Andrea Minervini; Lorenzo Masieri; Angelo Porreca; Stefano Zaramella; Bernardo Rocco
Journal:  Minerva Urol Nefrol       Date:  2015-03-03       Impact factor: 3.720

3.  Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer.

Authors:  Frank-Jan H Drost; Daniël F Osses; Daan Nieboer; Ewout W Steyerberg; Chris H Bangma; Monique J Roobol; Ivo G Schoots
Journal:  Cochrane Database Syst Rev       Date:  2019-04-25
  3 in total
  1 in total

1.  Predictors of upgrading from low-grade cancer at prostatectomy in men with biparametric magnetic resonance imaging.

Authors:  Ola Christiansen; Ola Bratt; Øyvind Kirkevold; Jūratė Šaltytė Benth; Pathmakulendran Manoharan; Anders Selnes; Erik Skaaheim Haug; Marit Slaaen
Journal:  Cent European J Urol       Date:  2022-12-31
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.